Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29642175 | 1.00 | ACACB (0.47) | ACACBACACA | |
| SCHEMBL21816549 | 1.00 | ACACB (0.47) | ACACBACACA | |
| SCHEMBL29700513 | 1.00 | ACACB (0.47) | ACACBACACA | |
| SCHEMBL14945398 | 1.00 | ACACB (0.47) | ACACBACACA | |
| SCHEMBL14945382 | 0.89 | ACACA (0.47) | ACACBACACA | |
| SCHEMBL21876832 | 0.89 | ACACA (0.47) | ACACBACACA | |
| SCHEMBL14945585 | 0.88 | ACACB (0.41) | ACACBACACA | |
| SCHEMBL18908171 | 0.87 | ACACB (0.44) | ACACBACACA | |
| SCHEMBL17580347 | 0.86 | ACACB (0.43) | ACACBACACA | |
| SCHEMBL21980409 | 0.86 | ACACB (0.45) | ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110950884-B | Di-ring derivative-containing inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-03-26 | — | — | CN | disclosed |
| US-11912718-B2 | Solid forms of a thienopyrimidinedione ACC inhibitor and methods for production thereof | GILEAD APOLLO, LLC (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912718-B2 | Solid forms of a thienopyrimidinedione ACC inhibitor and methods for production thereof | GILEAD APOLLO, LLC (US) | 2024-02-27 | — | — | US | disclosed |
| EP-3589636-B1 | PROCESSES FOR PREPARING ACC INHIBITORS AND SOLID FORMS THEREOF | GILEAD SCIENCES INC (US) | 2023-09-13 | — | — | EP | disclosed |
| CN-116745299-A | Thienopyrimidine derivatives | 正大天晴药业集团股份有限公司 | 2023-09-12 | — | — | CN | disclosed |
| EP-3660023-B1 | THIENOPYRIMIDINEDIONE COMPOUNDS AS ACC INHIBITORS AND USE THEREOF | NANJING SANHOME PHARMACEUTICAL CO LTD (CN) | 2023-03-08 | — | — | EP | disclosed |
| US-20230002405-A1 | ACC INHIBITOR AND USE THEREOF | NANJING RUIJIE PHARMA CO., LTD. (CN) | 2023-01-05 | — | — | US | disclosed |
| CN-112739705-B | Spiro compound and medical application thereof | 中国医药研究开发中心有限公司 | 2022-08-16 | — | — | CN | disclosed |
| CN-110431143-B | Heteroaryl pyrimidone derivatives, and preparation method and application thereof | 浙江海正药业股份有限公司 | 2022-08-12 | — | — | CN | disclosed |
| CN-110431144-B | Cyano-substituted heteroaryl pyrimidone derivatives, and preparation method and application thereof | 浙江海正药业股份有限公司 | 2022-08-05 | — | — | CN | disclosed |
| US-20160297834-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC | 2016-10-13 | — | — | US | disclosed |
| US-20160185799-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC | 2016-06-30 | — | — | US | disclosed |
| US-20160185799-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC | 2016-06-30 | — | — | US | disclosed |
| US-20150203510-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC | 2015-07-23 | — | — | US | disclosed |
| US-20150203510-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC | 2015-07-23 | — | — | US | disclosed |
| US-8969557-B2 | ACC inhibitors and uses thereof | Nimbus Apollo, Inc. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969557-B2 | ACC inhibitors and uses thereof | Nimbus Apollo, Inc. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20130123231-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123231-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. (US) | 2013-05-16 | — | — | US | disclosed |
| WO-2013071169-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. (US) | 2013-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912718-B2 | Solid forms of a thienopyrimidinedione ACC inhibitor and methods for production thereof | ACACA, ACACB, COASY | ACACB 2/4885ACACA 1/4885 |
| US-20150203510-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | ACACB 2/4885ACACA 1/4885 |
| US-20230002405-A1 | ACC INHIBITOR AND USE THEREOF | ACACA, ACACB, ACAT1 | ACACB 2/4885ACACA 1/4885 |
| US-20160185799-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | ACACB 2/4885ACACA 1/4885 |
| US-20130123231-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | ACACB 2/4885ACACA 1/4885 |
| US-20160297834-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | ACACB 2/4885ACACA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.